In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology, can be used to evaluate the body’s effect on drugs.

In this video, he highlights a poster, originally presented at the ELRIG Drug Discovery 2024 conference, in London – “Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS, a promising tool for more predictive studies of human drug ADME and oral bioavailability.”

The poster details the dual-organ MPS, the PhysioMimix® Gut/Liver-on-a-chip, which fluidically connects primary human gut and liver cells to better predict drug ADME parameters, such as bioavailability. The gut model utilizes RepliGut® Planar-Jejunum from Altis Biosystems, while the liver tissue leverages CN Bio’s FDA-recognized Liver-on-a-chip model.

This dual-organ model is also available as kit. The PhysioMimix Bioavailability assay kit: Human 18 is the only in vitro bioavailability assessment tool on the market; revolutionizing ADME studies by offering a solution for the simultaneous profiling of oral and intravenous drug bioavailability in vitro.